Varenicline is not routinely recommended during pregnancy. It should only be used when the potential benefit of smoking cessation outweighs the potential risk to the fetus, and this decision must be made with a healthcare professional.
The usual regimen begins one week before the planned quit date, allowing the medication to reach steady-state levels and begin reducing cravings ahead of the quit attempt.
Most users do not experience impairment, but some report vivid dreams or dizziness. If you feel drowsy or unsteady, avoid driving or operating heavy equipment until you know how the medication affects you.
Concurrent use can increase nicotine-related side effects such as nausea and dizziness. Combination therapy should only be undertaken if specifically prescribed and closely monitored.
Vivid dreams are a common side effect. Taking the evening dose earlier in the day or discussing dose timing with your prescriber may help. Persistent sleep disturbances should be reported to a clinician.
For mild to moderate renal impairment (creatinine clearance 30-60 mL/min), the dose is typically reduced to 0.5 mg twice daily after the initial titration period. Severe impairment usually contraindicates use.
Varenicline can be used in patients with a history of depression, but close monitoring for worsening mood or suicidal thoughts is essential. Discuss your mental health history with your prescriber before starting therapy.
Keep the tablets in their original packaging, at room temperature, and away from direct sunlight. If you are crossing international borders, carry a copy of the prescription and be prepared for possible medication checks.
Varenicline works by partially stimulating nicotine receptors and blocking nicotine’s effects, whereas NRT provides a controlled dose of nicotine to alleviate withdrawal. They have different mechanisms and side-effect profiles; both aim to support quitting but are not typically used together.
Some studies have explored varenicline’s effect on alcohol craving, but the evidence is not strong enough for an approved indication. Use for this purpose should only be considered in a research setting or under specialist advice.
Varenicline is a prescription medication used to help people stop smoking. It contains varenicline tartrate as its active ingredient and belongs to the therapeutic class of addiction-treatment agents, specifically for nicotine dependence. In the United Kingdom, varenicline is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is supplied as an oral pill in strengths of 0.5 mg and 1 mg. The drug is taken under medical supervision and is not available over the counter.
Varenicline is a partial agonist at the α4β2 subtype of neuronal nicotinic acetylcholine receptors. By binding to these receptors, it produces a moderate level of stimulation that reduces cravings and withdrawal symptoms associated with nicotine abstinence. At the same time, it blocks nicotine from binding to the same receptors, thereby decreasing the rewarding effects of smoking if a person relapses. The onset of action begins within a few hours of the first dose, with peak plasma concentrations reached in about 3-4 hours. The drug’s half-life is approximately 24 hours, allowing once-daily dosing after the titration phase.
Varenicline is approved in the UK for smoking cessation in adult smokers who are motivated to quit. The indication covers use as a stand-alone therapy; it may be combined with behavioural support programmes. It is not indicated for use in people under 18 years of age.
These effects are usually mild to moderate and tend to lessen after the first two weeks of therapy. Taking the medication with food may reduce nausea.
| Week | Dose per day | Total daily dose | ||--|| | 1-3 | 0.5 mg once daily (Week 1) → 0.5 mg twice daily (Weeks 2-3) | 0.5 mg → 1 mg | | 4-12 | 1 mg twice daily | 2 mg |
The treatment course typically lasts 12 weeks. Some clinicians may prescribe an additional 12-week maintenance phase for highly motivated patients who have successfully quit.
If a dose is missed and the next scheduled dose is more than 8 hours away, take the missed dose as soon as remembered. Do not double up to catch up.
Signs of overdose may include severe nausea, vomiting, dizziness, or fainting. Seek urgent medical assistance; activated charcoal may be considered if presentation is early. No specific antidote exists.
Varenicline should be stopped under medical guidance. No tapering is required, but patients should be prepared for potential rebound cravings and may benefit from continued behavioural support.
This article provides educational information about varenicline and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
